Gilead Sciences Partnership Update
Gilead Sciences, a biopharmaceutical company, has maintained its partnership with Cognizant, a global technology consulting firm. As of January 30, 2025, the partnership has been expanded to enhance efficiency and AI integration.
Partnership Details
- The partnership between Gilead Sciences and Cognizant was expanded on January 30, 2025.
- The updated partnership aims to improve efficiency and integrate AI capabilities.
Stock Performance
Gilead Sciences’ stock has demonstrated a notable price range over the past year. Key metrics include:
- 52-week high: $100.51 USD on February 4, 2025
- 52-week low: $62.07 USD on May 30, 2024
- Price-to-earnings ratio: 968.61
- Price-to-book ratio: 6.55681